Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting68Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer

Research output: Contribution to journalArticlepeer-review


Objective:68Ga-NGUL is a novel prostate-specific membrane antigen (PSMA)-targeting tracer based on Glu-Urea-Lys derivatives conjugated to a 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) chelator via a thiourea-type short linker. This phase I clinical trial of68Ga-NGUL was conducted to evaluate the safety and radiation dosimetry of68Ga-NGUL in healthy volunteers and the lesion detection rate of68Ga-NGUL in patients with prostate cancer. Materials and Methods: We designed a prospective, open-label, single-arm clinical trial with two cohorts comprising six healthy adult men and six patients with metastatic prostate cancer. Safety and blood test-based toxicities were monitored throughout the study. PET/CT scans were acquired at multiple time points after administering68Ga-NGUL (2 MBq/kg; 96–165 MBq). In healthy adults, absorbed organ doses and effective doses were calculated using the OLINDA/EXM software. In patients with prostate cancer, the rates of detecting suspicious lesions by68Ga-NGUL PET/CT and conventional imaging (CT and bone scintigraphy) during the screening period, within one month after recruitment, were compared. Results: All 12 participants (six healthy adults aged 31–32 years and six prostate cancer patients aged 57–81 years) completed the clinical trial. No drug-related adverse events were observed. In the healthy adult group,68Ga-NGUL was rapidly distributed, with the highest uptake in the kidneys. The median effective dose coefficient was calculated as 0.025 mSv/MBq, and cumulative activity in the bladder had the highest contribution. In patients with metastatic prostate cancer, 229 suspicious lesions were detected using either68Ga-NGUL PET/CT or conventional imaging. Among them,68Ga-NGUL PET/CT detected 199 (86.9%) lesions and CT or bone scintigraphy detected 114 (49.8%) lesions. Conclusion:68Ga-NGUL can be safely applied clinically and has shown a higher detection rate for the localization of metastatic lesions in prostate cancer than conventional imaging. Therefore,68Ga-NGUL is a valuable option for prostate cancer imaging.

Original languageEnglish
Pages (from-to)911-920
Number of pages10
JournalKorean Journal of Radiology
Issue number9
StatePublished - Sep 2022


  • Dosimetry
  • Ga-NGUL
  • PET/CT
  • PSMA
  • Prostate cancer


Dive into the research topics of 'Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting68Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer'. Together they form a unique fingerprint.

Cite this